Singular Highlights Key G4X™ Launch Milestones and Showcases Groundbreaking 3D Spatial Multiomic Performance at AGBT

Core Insights - Singular Genomics Systems, Inc. announced key development milestones for its G4X™ Spatial Sequencer at the AGBT conference, emphasizing its role in advancing precision medicine [1] G4X Early Access Program - The G4X Early Access Program is currently active at Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center, providing valuable feedback on the platform's real-world potential [2] - Feedback from early access sites highlights the G4X's high throughput and ability to generate high-quality data across multiple sample types, aligning with the needs of the spatial biology field [3] Performance and Capabilities - The G4X platform demonstrated robust integrated multiomic performance, showing high sensitivity, specificity, and reproducibility in FFPE samples across various cancer types [5] - Advanced 3D multi-omic reconstruction was showcased, analyzing over 6.2 million cells and 438 million transcripts from a single G4X flow cell [6] - The system's ability to measure transcripts, proteins, and fH&E within the same sample enhances reproducibility and facilitates advanced spatial analyses of immune-tumor interactions [7] Technological Advancements - Singular advanced its Direct-Seq technology, enabling accurate sequencing of T- and B-cell receptors in FFPE tonsil samples [8] - Researchers can access raw and demo datasets from multi-tissue performance studies to validate the platform's capabilities [9] Company Overview - Singular Genomics develops next-generation sequencing and multiomics technologies, with the G4® Sequencing Platform already commercially available and the G4X™ Spatial Sequencer currently in development [10]